London-based MedTech startup Acurable produces wearable medical devices that allow patients to be diagnosed and monitored at home. Its tech is focused on respiratory conditions such as sleep apnoea and COPD, aiming to reduce pressure on the healthcare system. Small in size and efficiency, its sensors are easy to use and, crucially, able to reduce the need for a specialist in the process of diagnosing conditions.
Acurable is responding to two major market trends. Firstly, the market for self-managed health has boomed in recent years. Consumers are already using devices such as Fitbits to track their exercise and sleep, and Acurable is betting on people taking a similar interest in their medical health. Secondly, one of healthcare's most pressing challenges is the cost of using specialists to diagnose patients. Suppose Acurable can move diagnosis away from doctors and into homes. In that case, it can free up valuable medical practitioners for the real problems that demand their expertise - boosting the company and the healthcare system.
The company's flagship product, AcuPebble SA100, was the first medical device in the world to receive CE marking for the automated diagnosis of obstructive sleep apnoea at home. If Acurable can continue the fast growth it has seen so far, it could revolutionise how we diagnose respiratory conditions. Backed by major investors and having won awards such as the XPrize, IET Innovation Award and WA4STEAM Award, it is currently expanding its remit to conditions including asthma, epilepsy and COPD.
Steph
Company Specialist at Welcome to the Jungle